Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | GPR139 | Q6DWJ6 | 6/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31359013 | 0.89 | GPR139 (0.59) | TP53KMT2AMEN1KDM4EGPR139 | |
| SCHEMBL31359086 | 0.89 | GPR139 (0.59) | TP53KMT2AMEN1KDM4EGPR139 | |
| SCHEMBL31359009 | 0.89 | GPR139 (0.56) | KMT2AMEN1KDM4EGPR139CYP1A2 | |
| SCHEMBL31359061 | 0.89 | GPR139 (0.56) | KMT2AMEN1KDM4EGPR139CYP1A2 | |
| SCHEMBL31359106 | 0.88 | KMT2A (0.48) | KMT2AMEN1KDM4EGPR139CYP1A2 | |
| SCHEMBL31359079 | 0.86 | MAPK10 (0.58) | KMT2AMEN1KDM4EGPR139MAPT | |
| SCHEMBL31359060 | 0.83 | GPR139 (0.48) | TP53KMT2AMEN1KDM4EGPR139 | |
| SCHEMBL31359070 | 0.83 | GPR139 (0.49) | KMT2AMEN1KDM4EGPR139CYP1A2 | |
| SCHEMBL31358967 | 0.82 | CYP1A2 (0.47) | KMT2AMEN1KDM4EGPR139CYP1A2 | |
| SCHEMBL31359010 | 0.81 | GPR139 (0.60) | GPR139SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12559464-B2 | Quinazolinone dione compounds and uses thereof | EDGEWISE THERAPEUTICS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| US-20250026726-A1 | QUINAZOLINONE DIONE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS, INC. | 2025-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250026726-A1 | QUINAZOLINONE DIONE COMPOUNDS AND USES THEREOF | TNNI3, TNNT2, MYLK2 | TP53 3989/4885KMT2A 4427/4885MEN1 2683/4885 |
| US-12559464-B2 | Quinazolinone dione compounds and uses thereof | TNNI3, TNNT2, TNNC1 | TP53 4525/4885KMT2A 4584/4885MEN1 3559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.